秦安股份(603758.SH):再次追加授權可使用不超2億元期貨投資收益繼續進行期貨投資及原材料套期保值業務
格隆匯 8 月 12日丨秦安股份(603758.SH)公佈,截至2020年8月6日,公司期貨投資累計收益為44631.61萬元。基於公司期貨收益情況,公司董事會同意再次追加授權經營管理層未來可使用不超過2億元期貨投資收益繼續進行期貨投資及原材料套期保值業務。前述事項已經公司第三屆董事會第二十四次會議審議通過,授權有效期至2021年6月30日止。
經公司第三屆董事會第二十四次會議審議通過授權額度調整後,公司可用於期貨投資及原材料套期保值業務的額度累計不超過9億元,其中本金5億元,投資收益4億元。在上述額度及授權期限內,資金可以滾動使用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.